Emergency and Critical Care Centre, Sapporo City General Hospital.
Department of Emergency Medicine, Hokkaido University Hospital, Sapporo, Hokkaido.
Medicine (Baltimore). 2021 Mar 12;100(10):e25099. doi: 10.1097/MD.0000000000025099.
The occurrence of massive hemorrhages in various emergency situations increases the need for blood transfusions and the risk of mortality. Use of fibrinogen concentrate (FC) may increase plasma fibrinogen levels more rapidly than the use of fresh-frozen product or cryoprecipitate. However, thus far, the efficacy of FC in significantly improving the risk of mortality and significantly reducing transfusion requirements has not been effectively demonstrated in several systematic reviews and meta-analyses.
We will conduct a systematic review and meta-analysis of FC for hemorrhages in emergency situations. We will include controlled trials, but will exclude randomized controlled trials in elective surgeries. We will include patients with hemorrhages in emergency situations. Intervention will be emergency supplementation of FC. The control group will be administered with ordinal transfusion or placebo. The primary outcome of the study is in-hospital mortality.We will search in electronic databases such as MEDLINE (PubMed), Web of Science, and the Cochrane Central Register of Controlled Trials. Two reviewers will independently screen the title and abstract, retrieve the full text of the selected articles, and extract the essential data. We will apply uniform criteria for evaluating the risk of bias associated with individual randomized controlled trial based on the Cochrane risk of bias tool. Values of the risk ratio will be expressed as a point estimate with 95% confidence intervals (CIs). Data of continuous variables will be expressed as the mean difference along with their 95% CIs and P values. We will assess the strength of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach.
This systematic review will provide physicians with updated information on the efficacy and safety of using FC for hemorrhage in emergency settings. Approval from the ethics board and patient consent were not required in our study.This study protocol has been funded through a protocol registry. The registry number is UMIN000041598.
在各种紧急情况下大量出血的发生增加了输血的需求和死亡率。纤维蛋白原浓缩物(FC)的使用可能比新鲜冷冻产品或冷沉淀更快地增加血浆纤维蛋白原水平。然而,到目前为止,几项系统评价和荟萃分析并未有效证明 FC 在显著降低死亡率风险和显著减少输血需求方面的疗效。
我们将对 FC 在紧急情况下出血的治疗进行系统评价和荟萃分析。我们将包括对照试验,但将排除选择性手术中的随机对照试验。我们将包括在紧急情况下出血的患者。干预措施将是 FC 的紧急补充。对照组将接受序贯输血或安慰剂治疗。该研究的主要结局是住院死亡率。我们将在电子数据库中进行搜索,如 MEDLINE(PubMed)、Web of Science 和 Cochrane 对照试验中心注册库。两名评审员将独立筛选标题和摘要,检索选定文章的全文,并提取基本数据。我们将根据 Cochrane 偏倚风险工具,应用统一的标准评估与单个随机对照试验相关的偏倚风险。风险比的值将作为点估计表示,带有 95%置信区间(CI)。连续变量的数据将表示为平均值差异及其 95%CI 和 P 值。我们将使用推荐评估、制定和评估方法来评估证据的强度。
本系统评价将为医生提供有关在紧急情况下使用 FC 治疗出血的疗效和安全性的最新信息。我们的研究不需要伦理委员会的批准和患者同意。本研究方案已通过方案注册获得资助。注册号为 UMIN000041598。